Bishop, Felicity L., Cross, Nadia, Dewar-Haggart, Rachel, Teasdale, Emma, Herbert, Amy, Robinson, Michelle E., Ridd, Matthew J., Mallen, Christian D., Clarson, Lorna E., Bostock, Jennifer, Becque, Taeko, Stuart, Beth, Garfield, Kirsty, Morrison, Leanne, Pollet, Sebastien, Vennik, Jane, Atherton, Helen, Howick, Jeremy, Leydon, Geraldine, Nuttall, Jacqui, Islam, Nazrul, Lee, Paul H., Little, Paul and Everitt, Hazel (2024) Talking in Primary Care (TIP): protocol for a cluster-randomised controlled trial in UK primary care to assess clinical and cost effectiveness of communication skills e-learning for practitioners on patients musculoskeletal pain and enablement. BMJ Open, 14 (3), [e081932]. (doi:10.1136/bmjopen-2023-081932).
Abstract
Introduction Effective communication can help optimise healthcare interactions and patient outcomes. However, few interventions have been tested clinically, subjected to cost-effectiveness analysis or are sufficiently brief and well-described for implementation in primary care. This paper presents the protocol for determining the effectiveness and cost-effectiveness of a rigorously developed brief eLearning tool, EMPathicO, among patients with and without musculoskeletal pain. Methods and analysis A cluster randomised controlled trial in general practitioner (GP) surgeries in England and Wales serving patients from diverse geographic, socioeconomic and ethnic backgrounds. GP surgeries are randomised (1:1) to receive EMPathicO e-learning immediately, or at trial end. Eligible practitioners (eg, GPs, physiotherapists and nurse practitioners) are involved in managing primary care patients with musculoskeletal pain. Patient recruitment is managed by practice staff and researchers. Target recruitment is 840 adults with and 840 without musculoskeletal pain consulting face-to-face, by telephone or video. Patients complete web-based questionnaires at preconsultation baseline, 1 week and 1, 3 and 6 months later. There are two patient-reported primary outcomes: pain intensity and patient enablement. Cost-effectiveness is considered from the National Health Service and societal perspectives. Secondary and process measures include practitioner patterns of use of EMPathicO, practitioner-reported self-efficacy and intentions, patient-reported symptom severity, quality of life, satisfaction, perceptions of practitioner empathy and optimism, treatment expectancies, anxiety, depression and continuity of care. Purposive subsamples of patients, practitioners and practice staff take part in up to two qualitative, semistructured interviews. Ethics approval and dissemination Approved by the South Central Hampshire B Research Ethics Committee on 1 July 2022 and the Health Research Authority and Health and Care Research Wales on 6 July 2022 (REC reference 22/SC/0145; IRAS project ID 312208). Results will be disseminated via peer-reviewed academic publications, conference presentations and patient and practitioner outlets. If successful, EMPathicO could quickly be made available at a low cost to primary care practices across the country. Trial registration number ISRCTN18010240.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.